| [1] |
.Science，1994，263（5151）：1281?1284.
|
| [2] |
Chiarle R，Voena C，Ambrogio C，et al.The anaplastic lymphoma kinase in the pathogenesis of cancer［J］.Nat Rev Cancer，2008，8（1）：11?23.
|
| [3] |
Sasaki T，Rodig SJ，Chirieac LR，et al.The biology and treatment of EML4-ALK non-small cell lung cancer［J］.Eur J Cancer，2010，46（10）：1773?1780.
|
| [4] |
Soda M，Choi YL，Enomoto M，et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer［J］.Nature，2007，448（7153）：561?566.
|
| [5] |
Golding B，Luu A，Jones R，et al.The function and therapeutic targeting of anaplastic lymphoma kinase （ALK） in non-small cell lung cancer （NSCLC）［J］.Mol Cancer，2018，17（1）：1?15.
|
| [6] |
Roskoski R.Anaplastic lymphoma kinase （ALK） inhibitors in the treatment of ALK-driven lung cancers［J］.Pharmacol Res，2017，117：343?356.
|
| [7] |
Kwak EL，Bang YJ，Camidge DR，et al.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer［J］.N Engl J Med，2010，363（18）：1693?1703.
|
| [8] |
Casaluce F，Sgambato A，Sacco PC，et al.Resistance to crizotinib in advanced non-small cell lung cancer （NSCLC） with ALK rearrangement：mechanisms，treatment strategies and new targeted therapies［J］.Curr Clin Pharmacol，2016，11（2）：77?87.
|
| [9] |
Gainor J，Dardaei L，Yoda S，et al.Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer［J］.Cancer Discov，2016，6（10）：1118?1133.
|
| [10] |
Shaw AT，Friboulet L，Leshchiner I，et al.Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F［J］.N Engl J Med，2016，374（1）：54?61.
|
| [11] |
Yarden Y，Elkabets M.Resistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathways［M］.Cham：Springer International Publishing，2018.
|
| [12] |
Lin JJ，Riely GJ，Shaw AT.Targeting ALK：precision medicine takes on drug resistance［J］.Cancer Discov，2017，7（2）：137?155.
|
| [13] |
Kong X，Pan P，Sun H，et al.Drug discovery targeting anaplastic lymphoma kinase （ALK）［J］.J Med Chem，2019，62（24）：10927?10954.
|
| [14] |
Lin JJ，Shaw AT.Resisting resistance：targeted therapies in lung cancer［J］.Trends Cancer，2016，2（7）：350?364.
|
| [15] |
Doebele RC，Pilling AB，Aisner DL，et al.Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer［J］.Clin Cancer Res，2012，18（5）：1472?1482.
|
| [16] |
Katayama R，Shaw AT，Khan TM，et al.Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers［J］.Sci Transl Med，2012，4（120）：120ra17.
|
| [17] |
Ou SHI，Azada M，Hsiang DJ，et al.Next-generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib （CH5424802/RO5424802） in ALK-rearranged NSCLC patients who progressed on crizotinib［J］.J Thorac Oncol，2014，9（4）：549?553.
|
| [18] |
Jamme P，Descarpentries C，Gervais R，et al.Relevance of detection of mechanisms of resistance to ALK inhibitors in ALK-rearranged NSCLC in routine practice［J］.Clin Lung Cancer，2019，20（4）：297?304.
|
| [19] |
Yamaguchi N，Lucena-Araujo AR，Nakayama S，et al.Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer［J］.Lung Cancer，2014，83（1）：37?43.
|
| [20] |
Kim HR，Kim WS，Choi YJ，et al.Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation［J］.Mol Oncol，2013，7（6）：1093?1102 .
|
| [21] |
Katayama R，Sakashita T，Yanagitani N，et al.P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer［J］.EBioMedicine，2016，3：54?66.
|
| [22] |
Nijenhuis CM，Haanen JB，Schellens JH，et al.Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma［J］？Cancer Treat Rev，2013，39（4）：305?312.
|
| [23] |
Shi JY，Bai Y，Peng KW，et al.Research progress of PARP-1 inhibitors in combination with other drugs to overcome drug resistance［J］.J China Pharm Univ（中国药科大大学学报），2019，50（5）：523?530.
|
| [24] |
Chen Z，Sasaki T，Tan X，et al.Inhibition of ALK，PI3K/MEK，and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene［J］.Cancer Res，2010，70（23）：9827?9836.
|
| [25] |
Sang J，Acquaviva J，Friedland JC，et al.Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer［J］.Cancer Discov，2013，3（4）：430?443.
|
| [26] |
Jhaveri K，Ochiana SO，Dunphy MP，et al.Heat shock protein 90 inhibitors in the treatment of cancer：current status and future directions［J］.Expert Opin Investig Drugs，2014，23（5）：611?628.
|
| [27] |
Yun MR，Lim SM，Kim SK，et al.Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors［J］.Cancer Res，2018，78（12）：3350?3362.
|
| [28] |
Fukuda K，Takeuchi S，Katayama R，et al.HDAC inhibition overcomes crizotinib-resistance by mesenchymal-epithelial transition （MET） in EML4-ALK lung cancer cells［J］.J Thorac Oncol，2017，12（1）：S382?S383.
|
| [29] |
Shen J，Najafi S，St?ble S，et al.A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment［J］.Cell Death Differ，2018，25（12）：2053?2070.
|
| [30] |
Asghar U，Witkiewicz AK，Turner NC，et al.The history and future of targeting cyclin-dependent kinases in cancer therapy［J］.Nat Rev Drug Discov，2015，14（2）：130?146.
|
| [31] |
Wood AC，Krytska K，Ryles HT，et al.Dual ALK and CDK4/6 inhibition demonstrates synergy against neuroblastoma［J］.Clin Cancer Res，2017，23（11）：2856?2868.
|
| [32] |
Isozaki H，Ichihara E，Takigawa N，et al.Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases［J］.Cancer Res，2016，76（6）：1506?1516.
|
| [33] |
Sasaki T，Koivunen J，Ogino A，et al.A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors［J］.Cancer Res，2011，71（18）：6051?6060.
|
| [34] |
Koh J，Jang JY，Keam B，et al.EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor （HIF）-1α and STAT3［J］.Oncoimmunology，2016，5（3）：e1108514.
|
| [35] |
Bylicki O，Paleiron N，Margery J，et al.Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non-small-cell lung cancer［J］.Target Oncol，2017，12（5）：563?569.
|
| [36] |
Felip E，de Braud FG，Maur M，et al.Ceritinib plus nivolumab （NIVO） in patients （pts） with anaplastic lymphoma kinase positive （ALK+） advanced non-small cell lung cancer （NSCLC）［J］.J Clin Oncol，2017，35（15_suppl）：2502.
|
| [37] |
Drilon A，Ou SI，Cho BC，et al.Repotrectinib （TPX-0005） is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations［J］.Cancer Discov，2018，8（10）：1227?1236.
|
| [38] |
Cui JJ，Zhai D，Deng W，et al.TPX-0005，a novel ALK/ROS1/TRK inhibitor，effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R，ROS1 G2032R and TRKA G595R mutants［J］.Eur J Cancer，2016，69：S32.
|
| [39] |
Zhai DY，Deng W，Huang J，et al.Abstract 3161：TPX-0005，an ALK/ROS1/TRK inhibitor，overcomes multiple resistance mechanisms by targeting SRC/FAK signaling［C］.Cancer Res，2017，77（13_suppl）：3161.
|
| [40] |
Xu M.Predicting inactive conformations of protein kinases （蛋白激酶非活性构象的预测方法研究）［D］.Shanghai：Fudan University，2019.
|
| [41] |
Blanc J，Geney R，Menet C.Type II kinase inhibitors：an opportunity in cancer for rational design［J］.Anti-Cancer Agents Med Chem，2013，13（5）：731?747.
|
| [42] |
Pan P，Yu H，Liu Q，et al.Combating drug-resistant mutants of anaplastic lymphoma kinase with potent and selective type-I1/2 inhibitors by stabilizing unique DFG-shifted loop conformation［J］.ACS Cent Sci，2017，3（11）：1208?1220.
|
| [43] |
Zhao Z，Wu H，Wang L，et al.Exploration of type II binding mode：a privileged approach for kinase inhibitor focused drug discovery［J］.ACS Chem Biol，2014，9（6）：1230?1241.
|
| [44] |
Tu CH，Lin WH，Peng YH，et al.Pyrazolylamine derivatives reveal the conformational switching between type I and type II binding modes of anaplastic lymphoma kinase （ALK）［J］.J Med Chem，2016，59（8）：3906?3919.
|
| [45] |
Mathi GR，Kang CH，Lee HK，et al.Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R［J］.Eur J Med Chem，2017，126：536?549.
|
| [46] |
Geng K，Xia Z，Ji Y，et al.Discovery of 2，4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation［J］.Eur J Med Chem，2018，144：386?397.
|
| [47] |
Chen YF，Wu JX，Wang AL，et al.Discovery of N-（5-（（5-chloro-4-（（2-（isopropylsulfonyl）phenyl）amino）pyrimidin-2-yl）amino）-4-methoxy-2-（4-methyl-1，4-diazepan-1-yl）phenyl）acrylamide （CHMFL-ALK/EGFR-050） as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC［J］.Eur J Med Chem，2017，139：674?697.
|
| [48] |
Ott GR，Cheng M，Learn KS，et al.Discovery of clinical candidate CEP-37440，a selective inhibitor of focal adhesion kinase （FAK） and anaplastic lymphoma kinase （ALK）［J］.J Med Chem，2016，59（16）：7478?7496.
|
| [49] |
Sun X，Rao Y.PROTACs as potential therapeutic agents for cancer drug resistance［J］.Biochemistry，2020，59（3）：240?249.
|
| [50] |
Zhang C，Han X，Yang X，et al.Proteolysis targeting chimeras （PROTACs） of anaplastic lymphoma kinase （ALK）［J］.Eur J Med Chem，2018，151：304?314.
|
| [51] |
Kang CH，Lee DH，Lee CO，et al.Induced protein degradation of anaplastic lymphoma kinase （ALK） by proteolysis targeting chimera （PROTAC）［J］.Biochem Biophys Res Commun，2018，505（2）：542?547.
|
百度学术
下载:
